Heritage Insurance Holdings, a super-regional property and casualty insurer, will release its third quarter 2026 financial results after market close on October 28, 2026. The company will hold a conference call at 9:00am ET on October 29 to discuss the results. Heritage writes about $1.4 billion in premiums across multiple states and focuses on catastrophe-related insurance. Investors can access the earnings call via phone or webcast on the company website.
Heritage Insurance Holdings is set to announce its Q3 2026 earnings on October 28, 2026. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: out of 142 priced Financials-sector US stocks, 42 rose and 99 fell today. Notable movers include BTBT at USD 0.91 with a 5.19% decline and 83% buy activity, PSEC at USD 1.52 down 5.00% with 100% buy activity, and FIGR at USD 25.78 down 4.98% with 100% buy activity and a typical hold time of 4 days on Pluang.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
